{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > DNA Damage & DNA Repai > Bendamustine HydrochlorideCAS：3543-75-7
Molecular Formula：C16H22Cl3N3O2
Molecular Weight：394.72
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 3543-75-7 |
| Name | Bendamustine Hydrochloride |
| Molecular Formula | C16H22Cl3N3O2 |
| Molecular Weight | 394.72 |
| Solubility | Soluble in Water/DMSO |
| Purity | HPLC≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 631-540-0 |
| MDL | MFCD01658758 |
| SMILES | CN1C(C=CC(N(CCCl)CCCl)=C2)=C2N=C1CCCC(O)=O.Cl |
| Target Point | DNA Crosslinker |
| Passage | DNA Damage/DNA Repair |
| Background | Bendamustine hydrochloride is a DNA crosslinker. |
| Biological Activity | Bendamustine hydrochloride 是一种 DNA 交联剂 (DNA crosslinker)，能够导致 DNA 断裂，具有烷基化和抗代谢物的作用。[1-4] |
| In Vitro | 盐酸苯达莫司汀是一种DNA交联剂，可导致DNA断裂，具有烷基化和抗代谢特性。苯达莫司汀独特地调节非霍奇金淋巴瘤细胞中的凋亡途径和DNA修复途径。苯达莫司汀(50μM)诱导p21(Cip1 / Waf1)和NOXA基因，并增加SU-DHL-1细胞中p53的表达。苯达莫司汀(25μM)阻断有丝分裂检查点并引发有丝分裂灾难[1]。苯达莫司汀降低了多发性骨髓瘤(MM)细胞系(如RPMI-8226和8226-LR5细胞)的活力，孵育24小时后IC25分别为101.8和585.5μM，孵育48小时后分别为51.7和374.3μM。苯达莫司汀诱导特异性半胱天冬酶依赖性MM细胞死亡并抑制纺锤体组装检查点[2]。 |
| In Vivo | 苯达莫司汀(25 mg / kg，iv)对DoHH-2，Granta 519和RAMOS模型的肿瘤细胞生长分别有91％，99％和95％的有效抑制作用。此外，在DoHH-2和RAMOS模型中利妥昔单抗增强了苯达莫司汀的抗肿瘤作用，但在Granta 519模型中没有[3]。 |
| Cell Experiment | 苯达莫司汀和美法仑对多发性骨髓瘤(MM)细胞的细胞毒性计算为通过MTS测定法测量细胞存活百分比来抑制细胞活力。简而言之，将细胞(1×10 4 /孔)接种在具有递增浓度的药物的96孔板中，并在孵育24，48，72和96小时后进行分析。为此，向每个孔中加入1μg/ mL MTS溶液，在37℃下1小时后，用1N异丙醇和HCl(24：1，体积/体积)溶解深蓝色甲crystals晶体。最后，在96孔板读数器中在490nm处测量吸光度。将细胞存活估计为未处理对照的吸光度百分比，并且每个测试一式三份进行。计算每种药物的抑制浓度50(IC50)和25(IC25)，即能够将细胞生长分别降低至未处理对照细胞的50％和25％的量，并且测试并行进行使用等毒浓度的苯达莫司汀和美法仑。相对抗性指数(RRI)表示为8226-LR5的IC50与RPMI-8226细胞的IC50的比值[2]。 |
| Animal Experiment | 小鼠[3] CB-17 scid小鼠(DoHH-2，Granta 519)或CB-17 scid-bg小鼠(SuDHL-4，RAMOS)接种1×106(DoHH-2，RAMOS)，3×106(SuDHL-4)或5×106(Granta 519)细胞sc在右胁腹。对于侧腹异种移植物，接种体积为0.2mL，由生长培养基和基质胶中50:50的细胞混合物组成。通过电子卡尺每周两到三次测量肿瘤的长度和宽度并且应用以下等式来估计肿瘤体积：V = L×W2 / 2。允许肿瘤达到约250mm 3，并且将小鼠与治疗组和对照组进行大小匹配(第0天)。对于系统性Granta 519肿瘤模型，在第0天通过尾静脉在0.1mL体积的细胞培养基中注射2×10 6个细胞，并在第14天开始治疗。在整个实验过程中对所有动物进行耳标记和单独监测。通过口服管饲法每天一次在Phosal 50PG：PEG400：乙醇的混合物中施用Navitoclax。在第1天，苯达莫司汀和利妥昔单抗分别以25mg / kg和10mg / kg静脉内给药。在苯达莫司汀和利妥昔单抗之前约2小时给予Navitoclax。所有试验均由每组10只小鼠组成。当肿瘤达到> 2000 mm3的大小或监测到任何窘迫迹象时，小鼠被人道地杀死。窘迫的迹象包括失去走动，呼吸困难或体重减轻>每笼平均体重20％[3]。 |
| Data Literature Source | [1]. Leoni LM， et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1; 14 (1) :309-17. [2]. Cives M， et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May; 25 (5) :1108-17. [3]. Ackler S， et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct; 167 (4) :881-91. [4]. Minbo Zang， et al. Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice. J Biomed Res. 2017 0 (0) : 1-12. |
| Unit | Bottle |
| Specification | 50mg 100mg 500mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
